معرفی
Marte Lie Høivik is a Professor at the University of Oslo's Institute of Clinical Medicine, Department of Gastroenterology and Hepatology. She serves as Senior Consultant and Head of the IBD Unit at Oslo University Hospital, leading the IBD research group and directing the IBSEN III study.
Her research focuses on clinical and registry-based epidemiology in inflammatory bowel disease (IBD), with emphasis on clinical effectiveness, quality studies, prognostic research, and biomarker identification. Her work leverages large population-based cohorts like IBSEN to investigate disease course, treatment outcomes, and quality-of-life impacts.
Recent publications reveal strong trends in risk prediction modeling, microbiome analysis, therapeutic drug monitoring, and real-world treatment effectiveness. Her team frequently examines understudied aspects like fatigue in remission, dietary impacts, and sex/gender differences in IBD outcomes using longitudinal cohort designs.
Høivik actively supervises research within the IBSEN III cohort and collaborates extensively across Nordic countries on IBD epidemiology. Her team has published over 30 papers since 2021 in high-impact journals including Nature, Gastroenterology, and The Lancet Gastroenterology & Hepatology.
She leads multiple research projects including the IBSEN III cohort study and NORDTREAT, with current funding supporting investigations into biomarkers, treatment strategies, and long-term disease outcomes in inflammatory bowel disease.
